Abstract Number: 2529 • ACR Convergence 2023
Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
Background/Purpose: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than zoledronic acid (ZA), evidence from…Abstract Number: 0811 • ACR Convergence 2023
Comparative Effectiveness of Sodium-glucose cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-primary Emergency Department Visits and Hospitalizations: A General Population Cohort Study
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate (primary prevention); however, whether this translates into preventing recurrent flares among gout patients (secondary prevention) and gout-primary…Abstract Number: 2538 • ACR Convergence 2023
Safety and Efficacy of Sodium-glucose Co-transporter 2 Inhibitors in Patients with Psoriasis and Concomitant Type 2 Diabetes Mellitus: A Population-based Cohort Study
Background/Purpose: Psoriasis and type 2 diabetes mellitus (T2D) may share common underlying pathophysiology, in which the pathogenesis of psoriasis is mediated by NOD-like receptor family…Abstract Number: 0853 • ACR Convergence 2023
Early Experience with Avacopan for ANCA-Associated Vasculitis in a Large Integrated Healthcare System
Background/Purpose: ANCA-associated vasculitis (AAV) is a small-to-medium vessel vasculitis associated with substantial morbidity and mortality, in part due to glucocorticoid exposure. Avacopan, an oral C5a…Abstract Number: 1103 • ACR Convergence 2023
Evaluation of Outcomes Following Discontinuation of Pegloticase Therapy
Background/Purpose: Little is known about the long-term effects of pegloticase therapy or what urate-lowering therapy (ULT) patients subsequently receive when they discontinue pegloticase. This analysis…Abstract Number: 1340 • ACR Convergence 2023
Recent Trends in Treatment Patterns for Rheumatoid Arthritis in Response to Emerging Data
Background/Purpose: Janus kinase inhibitors (JAKi) have demonstrated substantial efficacy in decreasing symptoms and in reducing progressive joint damage in patients with rheumatoid arthritis (RA). In…Abstract Number: 1386 • ACR Convergence 2023
Opioid Prescription Rates in Patients with Ankylosing Spondylitis in the UK Between 2001-2020: An Electronic Health Records (EHR) Analysis
Background/Purpose: Although current axial spondyloarthritis (axSpA) management guidelines do not address opioid use for chronic pain, available data show that opioid use is common among…Abstract Number: 1515 • ACR Convergence 2023
Performance of the Revised CRISS in a Phase 3 Trial of Early Systemic Sclerosis
Background/Purpose: Revised CRISS has been proposed an approvable outcome measure in early diffuse cutaneous SSc (dcSSc)1. The index is undergoing the FDA review as part…Abstract Number: 1582 • ACR Convergence 2023
Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data
Background/Purpose: There is a paucity of data to guide biologic and JAKi DMARD selection in rheumatoid arthritis-interstitial lung disease (RA-ILD), with some reports of higher…Abstract Number: 109 • 2023 Pediatric Rheumatology Symposium
Long-term Safety of Biologics versus Conventional Synthetic Treatments in Systemic Juvenile Idiopathic Arthritis Patients
Background/Purpose: The better understanding of systemic Juvenile Idiopathic Arthritis (sJIA) pathogenesis and availability of new drugs, such as biologic disease-modifying anti-rheumatic drugs (bDMARDs) specifically dedicated…Abstract Number: 0862 • ACR Convergence 2022
Impact of the COVID-19 Pandemic on the Management of Juvenile Idiopathic Arthritis: An Analysis of National United States Administrative Claims Data
Background/Purpose: Limited information exists on COVID-19 pandemic-related changes in the management of rheumatic diseases in adults or children, besides what patients and families have reported.…Abstract Number: 0925 • ACR Convergence 2022
Impact of Initiating Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs on Pain Medication Use in Patients with Rheumatoid Arthritis
Background/Purpose: Chronic pain associated with rheumatoid arthritis (RA) leads to impaired patient function and quality of life. Prior studies suggest initiation of disease-modifying antirheumatic drugs…Abstract Number: 1112 • ACR Convergence 2022
Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patients with Inflammatory Arthritis in the DANBIO Registry
Background/Purpose: In routine care, biosimilar-to-biosimilar infliximab switching may occur to save costs (=non-medical switching). Previous studies have investigated the efficacy and safety of switches from…Abstract Number: 1199 • ACR Convergence 2022
Validation of New Medication User Definitions in Single-Specialty EHR Data
Background/Purpose: New user designs are standard in many pharmacoepidemiology studies, but a first prescription appearance in electronic health record (EHR) data may not always represent…Abstract Number: 1213 • ACR Convergence 2022
Trends of Opioid Prescriptions and Impact of the COVID-19 Pandemic Among Patients with Musculoskeletal Diseases Between 2006-2021
Background/Purpose: Opioid prescribing has contributed to a North American epidemic with increasing trends in several European countries. Rheumatic and musculoskeletal diseases (RMDs) are one of…
ACR Meeting Abstracts